Research

The CAVADEX® molecule

CAVADEX® (developed by Cholrem Pty Ltd) is a form of Hydroxypropyl beta cyclodextrin (HPßCD) that is comprised of seven sugar molecules bound together in a ring (cyclic oligosaccharide).

The ring-shaped, three-dimensional structure has a hydrophobic cavity in its center, which is capable of trapping cholesterol and lipids. It has been used extensively as an excipient in the food, deodorant, and drug industry for the past century, and it is generally recognized as safe (GRAS).

As an active ingredient, CAVADEX® entraps and removes intracellular cholesterol and lipids that can cause injury to the kidneys and other organs, including the brain and liver.

Cyclodextrin harmlessly absorbs cholesterol from cells

"Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques..."

nature.com : Molecule melts away cholesterol.

"Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques..."

sciencedaily.com : Drug used for rare disease may be able to treat heart disease.

"Soaked up cholesterol and removed it..."

sciencedaily.com : New hope for treating atheriosclerosis

"have the potential in lowering deaths caused by atherosclerosis..."

ntnu.co : Can a sugar treat atherosclerosis?

"can actually solubilize cholesterol and dissolve the plaques..."

huffpost.com : Cholesterol sweet spot.

Research studies

"Alzheimer disease"
A study on the effects of HP-B-CD in transgenic mice with Alzheimer disease showed a dramatic reduction in symptoms and significantly improved spatial learning and memory deficits in mice. The study concluded HP-B-CD could be a novel therapeutic strategy for Alzheimer disease.

"Diabetic kidney disease"
HP-B-CD has shown promising pre-clinical results in kidney disease. Progression of kidney disease was prevented in mouse models and diabetic kidney disease was prevented or partially prevented in two pre-clinical studies.

"Non-alcoholic fatty liver disease"
Several studies have shown that HP-B-CD reduces liver cholesterol and cholesterol crystals. HP-B-CD has a substantial effect on cholesterol distribution and cholesterol transporters.

"Improved eyesight"
Lipofuscin accumulation in the retinal pigment epithelium is a hallmark of aging. A study was done on the effects of cyclodextrin and found that the beta-cyclodextrin can bind retinal lipofuscin, prevent its oxidation and remove it.
Cholrem patients have also reported improved vision after treatments of CAVADEX®.

CAVADEX® removes plaque and cholesterol

plaque reduced in just 4 weeks

A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.

Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Improve Liver function

Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.

Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.

Cyclodextrin Publications

Cholrem p/l.

The CAVADEX® molecule

Related Articles

Research studies

CAVADEX® removes plaque and cholesterol

plaque reduced in just 4 weeks

Improve Liver function

Cyclodextrin Publications

About Cyclodextrins

Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease

Cyclodextrins and Non-renal Diseases

Cyclodextrins and Renal Disease